Literature DB >> 15289140

Early rapid rise in intraocular pressure after intravitreal triamcinolone acetonide injection.

Inder P Singh1, Sameer I Ahmad, David Yeh, Pratap Challa, Leon W Herndon, R Rand Allingham, Paul P Lee.   

Abstract

PURPOSE: To report the occurrences of early rapid increases in intraocular (IOP) after intravitreal glucocorticoid injection.
DESIGN: Observational case series.
METHODS: We retrospectively reviewed the records of three patients seen and treated at Duke Eye Center.
RESULTS: In all three cases, a significant rise in IOP occurred within 1 week of intravitreal triamcinolone injection for refractory macular edema. In one patient, a white material was found in the angle on gonioscopy. All three cases required surgical intervention to reduce the IOP.
CONCLUSIONS: Considering the early rapid rise in IOP in these three cases, we suggest that clinicians closely monitor patients after intravitreal triamcinolone injections for the development of acute glaucoma. Additionally, it may be advisable to perform gonioscopic examinations to look for any abnormal accumulation of material in the angle.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15289140     DOI: 10.1016/j.ajo.2004.03.001

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  22 in total

1.  Comparison of 4 mg versus 20 mg intravitreal triamcinolone acetonide injections.

Authors:  A M Tammewar; L Cheng; O R Kayikcioglu; I A Falkenstein; I Kozak; M H Goldbaum; W R Freeman
Journal:  Br J Ophthalmol       Date:  2008-04-17       Impact factor: 4.638

2.  Outcomes of Ahmed glaucoma valve implantation for steroid-induced elevated intraocular pressure in patients with retinitis pigmentosa.

Authors:  Umit Eksioglu; Caglar Oktem; Gulten Sungur; Mehmet Yakin; Gulizar Demirok; Firdevs Ornek
Journal:  Int Ophthalmol       Date:  2017-07-21       Impact factor: 2.031

3.  Postoperative outcomes after fluocinolone acetonide implant surgery in patients with birdshot chorioretinitis and other types of posterior and panuveitis.

Authors:  Bryn M Burkholder; Jiangxia Wang; James P Dunn; Quan D Nguyen; Jennifer E Thorne
Journal:  Retina       Date:  2013-09       Impact factor: 4.256

4.  Vehicle of triamcinolone acetonide is associated with retinal toxicity and transient increase of lens density.

Authors:  Wang Kai; Jiang Yanrong; Li Xiaoxin
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-02-02       Impact factor: 3.117

5.  Impact of injection techniques on intraocular pressure (IOP) increase after intravitreal ranibizumab application.

Authors:  Fabian Höhn; Alireza Mirshahi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-04-21       Impact factor: 3.117

6.  Predictive factors for short-term visual outcome after intravitreal triamcinolone acetonide injection for diabetic macular oedema: an optical coherence tomography study.

Authors:  Oswaldo Ferreira Moura Brasil; Scott D Smith; Anat Galor; Careen Y Lowder; Jonathan E Sears; Peter K Kaiser
Journal:  Br J Ophthalmol       Date:  2006-11-15       Impact factor: 4.638

7.  Development of ocular hypertension and persistent glaucoma after intravitreal injection of triamcinolone.

Authors:  M Selim Kocabora; Cemil Yilmazli; Muhittin Taskapili; Gokhan Gulkilik; Sahan Durmaz
Journal:  Clin Ophthalmol       Date:  2008-03

8.  Selective laser trabeculoplasty for elevated intraocular pressure following subtenon injection of triamcinolone acetonide.

Authors:  Kenya Yuki; Makoto Inoue; Daisuke Shiba; Ryosuke Kawamura; Susumu Ishida; Yuichiro Ohtake
Journal:  Clin Ophthalmol       Date:  2010-04-26

9.  Intraocular pressure elevation following triamcinolone acetonide administration as related to administration routes.

Authors:  Yoshio Hirano; Takeshi Ito; Miho Nozaki; Tsutomu Yasukawa; Eiji Sakurai; Munenori Yoshida; Yuichiro Ogura
Journal:  Jpn J Ophthalmol       Date:  2009-10-22       Impact factor: 2.447

10.  Impact on intraocular pressure after 20-mg decanted triamcinolone acetonide (kenalog) injection when using prophylactic antiglaucoma therapy.

Authors:  Giulio Barteselli; Payam Amini; Isaac C Ezon; Joseph T Nezgoda; Lingyun Cheng; William R Freeman
Journal:  Retina       Date:  2015-01       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.